cytotoxic t-lymphocytes

Phase 2Small molecule

cytotoxic t-lymphocytes is one of 4 small molecule programs targeting Epstein-Barr Virus Infections. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epstein-Barr Virus InfectionsRecruiting

AdenovirusRecruiting

Epstein-Barr Virus InfectionsPhase 2

Recruiting

AdenovirusPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Adenovirus

#DrugCompanyPhaseTrials

Adenovirus Specific T- Lymphocytes

JJessie L. Alexander

Phase 2

1 2

cytotoxic t-lymphocytes

NNew York Medical College

Phase 2

1 3

Cytomegalovirus Specific T-Lymphocytes

JJessie L. Alexander

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Adenovirus

NCT03266627

Phase 2Recruiting

Epstein-Barr Virus Infections

NCT03266653

Clinical

Trials by Indication[1]

Prophylaxis1 trial

Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV

Completed·MMedical College of Wisconsin·Phase 1·NCT01535885·25 enrolled

COVID-191 trial

Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

Completed·TThomas Jefferson University·Phase 1·NCT04765449·30 enrolled

Adenovirus1 trial

A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection With Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult Recipients

Recruiting·NNew York Medical College·Phase 2·NCT03266627·20 enrolled

Epstein-Barr Virus Infections1 trial

A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection With Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients

Recruiting·NNew York Medical College·Phase 2·NCT03266653·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for cytotoxic t-lymphocytes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cytotoxic t-lymphocytes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cytotoxic t-lymphocytes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York Medical College company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNew York Medical College

cytotoxic t-lymphocytes

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Prophylaxis1 trial

COVID-191 trial

Adenovirus1 trial

Epstein-Barr Virus Infections1 trial

References

Drug Info

Quick Facts

Related News